Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

ADXS opened at $0.03 on Wednesday. The business has a 50 day simple moving average of $0.03 and a 200-day simple moving average of $0.04. The stock has a market capitalization of $1.28 million, a P/E ratio of 0.00 and a beta of 1.68. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.78.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.